Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Development of gene expression profiles for murine breast tumours overexpression the transcription factor PRH

ABSTRACT: In order to establish a profile of gene expression of tumours overexpressing PRH we performed agilient microarray analysis on four 4T1 tumour samples engineered to overexpress PRH, and four control tumours with normal PRH expression. cancer, colorectal metastasis to the liver and matched healthy tissues. The tumours had recieved no treatement prior to resection. The expression profiles were compared by one colour microarray analysis between PRH overexpression and control tumours. Genes consistently differentially expressed between the groups were taken forward for further analysis. Preparation of the tumours: 4T1 cells were infected with Adenoviral-PRH or empty Adenovirus at MOI 50 for 24 hrs. Adenoviral constructs described in Kershaw, R.M., et al., PRH/HHex inhibits the migration of breast and prostate epithelial cells through direct transcriptional regulation of Endoglin. Oncogene, 2014. 33(49): p. 5592-600. Cells were washed 4x with PBS, trypsinised, washed and resuspended in Opti-memï£¨ (Invitrogen) at 1.25x106 cells/ml and kept on ice for 20-30 min before injection. Aliquots 200 Î¼l / 2.5x105 of the cells were injected into the no. 3 fat pad of 6-8 week old female BALB/C mice. Total RNA was extracted from each tumour using the Qiagen miRNAeasy kit, processed into cRNA using the Agilient low input, one colour labelling kit, hybridised onto the 8 x 66k whole human genome expression microarrays. Data was normalised in R64 and comparison matrices between matched Tumour and Healthy endothelum were constructed. Genes upregualated in all the comparisons were taken forward for further analysis.

ORGANISM(S): Mus musculus

SUBMITTER: Joseph Wragg

PROVIDER: E-GEOD-83319 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Development of gene expression profiles for murine breast tumours overexpression the transcription factor PRH

Project description:In order to establish a profile of gene expression of tumours overexpressing PRH we performed agilient microarray analysis on four 4T1 tumour samples engineered to overexpress PRH, and four control tumours with normal PRH expression. cancer, colorectal metastasis to the liver and matched healthy tissues. The tumours had recieved no treatement prior to resection. The expression profiles were compared by one colour microarray analysis between PRH overexpression and control tumours. Genes consistently differentially expressed between the groups were taken forward for further analysis. Preparation of the tumours: 4T1 cells were infected with Adenoviral-PRH or empty Adenovirus at MOI 50 for 24 hrs. Adenoviral constructs described in Kershaw, R.M., et al., PRH/HHex inhibits the migration of breast and prostate epithelial cells through direct transcriptional regulation of Endoglin. Oncogene, 2014. 33(49): p. 5592-600. Cells were washed 4x with PBS, trypsinised, washed and resuspended in Opti-mem (Invitrogen) at 1.25x106 cells/ml and kept on ice for 20-30 min before injection. Aliquots 200 μl / 2.5x105 of the cells were injected into the no. 3 fat pad of 6-8 week old female BALB/C mice.

2016-06-15 | GSE83319 | GEO

Development of gene expression profiles for murine breast tumours treated with Sunitinib

Project description:In order to establish a profile of gene expression of tumours treated with sunitinib, 4T1 breast tumours were allowed to establish in Balb/C mice for 1 week. The mice were then treated with 40 mg/kg Sunitinib in PBS and 3.72% DMSO (treatemt group) or PBS-DMSO vehicle alone (no treatment group), daily for the period of the experiment, after which the tumours were resected homogenised and subjected to CD31 microbead separation of endothelial cells and bulk tissue, both of which were subjected to agilent microarray analysis. Treated tumours greater than 250 mm3 (by caliper measurement) after 8 days of treatment were considered resistant to treatment, those smaller than this were considered sensitive to sunitinib treatment. Total RNA was extracted from each tumour sample using the Qiagen miRNAeasy kit, processed into cRNA using the Agilient low input, one colour labelling kit, hybridised onto the 8 x 66k whole mouse genome expression microarrays. Data was normalised in R64 and comparison matrices between treated and untreated endothelum and bulk fractions were constructed. Genes whose expression was significantly altered by sunitinib treatement were taken forward for further analysis.

2016-07-06 | E-GEOD-84048 | biostudies-arrayexpress

Genome-wide analysis of ex vivo gene expression of 4T1 series mouse mammary tumors

Project description:Analysis of factors upregulated in highly aggressive 410.4 and 4T1 tumour cells compared to the less aggressive 4T07 tumour cells at gene expression level. The question addressed in the present study was which secreted factors are differentially expressed by these cells and therefore could account for the observed difference in fibroblast activation in these tumours. Results provide important characterisation of the ex vivo expression profiles of highly aggressive vs. non-aggressive tumour cells. 4T07, 410.4 or 4T1 cells were inoculated into the mammary fat pad of Ub-GFP mice and total RNA from FACSorted GFP-negative; CD45-negative tumour cells was isolated.

2016-01-18 | E-GEOD-50471 | biostudies-arrayexpress

Specific endothelical cells govern nanoparticle entry into solid tumours

Project description:We sequenced the transcroptome of isolated nanoparticle positive and nanoparticle negative tumour endothelial cells from mouse 4T1 mammary tumours

2021-09-07 | GSE172496 | GEO

FADS1/2 control lipid metabolism and ferroptosis susceptibility in triple-negative breast cancer

Project description:Analysis of factors upregulated in highly aggressive 4T1 tumour cells compared to the less aggressive 4T07 tumour cells and the non-metastatic 67NR tumour cells at gene expression level. The question addressed in the present study was which metabolic pathways are differentially activated by these cells and therefore could account for the observed difference metastatic potential of these tumours. Results provide important characterisation of the ex vivo expression profiles of highly aggressive vs. non-aggressive tumour cells. 4T07 and 4T1 tumour cell data was previously published in GSE50471.

2024-05-13 | GSE236033 | GEO

Development of gene expression profiles for tumour derived endothelium vs. matched healthy tissues (in renal cell carcinoma, colorectal cancer and colorectal metastasis to the liver)

Project description:In order to establish a profile of tumour vascular expression which could potentially be targeted therapeutically, we performed agilient microarray analysis on 4 samples each or renal cell carcinoma, colorectal cancer, colorectal metastasis to the liver and matched healthy tissues. The tumours had recieved no treatement prior to resection. The expression profiles were compared by one colour microarray analysis between matched healthy and tumour tissue. Genes expressed in all/or most of the comparisons were taken forward for further analysis. See acompanying publication: Wragg JW, Finnity JP, Anderson JA, Ferguson HJM, Bhatt RI, Murray PG, Heath VL, Bicknell R. MCAM is a vascular target in renal cancer. Cancer Research. 2016. The endothelum was isolated using collagenase V digestion, and dynabead magnetic bead isolation conjugated to lectin from Ulex Europaeus (Ulex Europaeus Agglutinin I (UEA I)), which binds human endothelial cells.

2016-01-26 | GSE77199 | GEO

DNA accessibility in CD8+ tumour-infiltrating T cells treated with Phenelzine.

Project description:Phenelzine treatments were conducted in tumour-bearing Balb/c mice and then 4T1 tumours were acquired. CD8+ tumour-infiltrating T cells were positively selected by using mouse CD8a (Ly-2) microbeads and isolated by autoMACS Separator with recommended programs. Then isolated CD8 T cells were stimulated by PMA and Ionomycin. Global ATAC-seq analysis was performed to identify the dynamic changes in chromatin accessibility of tumour-filtrating CD8 T cells after phenelzine treatment.

2018-12-05 | GSE107724 | GEO

Genome-wide analysis of ex vivo gene expression of 4T1 series mouse mammary tumors

2016-01-18 | GSE50471 | GEO

A three marker signature to distinguish Small cell from large cell neuroendocrine carcinoma: Study at transcriptomic and protein level

Project description:To identify potential markers for distinction of Small cell (SCLC) from large cell neuroendocrine (LCNEC) carcinoma, we have conducted the gene expression profiling on precisely isolated cancer cells and bronchial epithelial cells from these tumours and normal background lung. After statistical analysis and finding highly differentially expressed genes between these tumour groups, we performed qRT-PCR to delineate markers to test at protein level using immunohistochemistry. Markers showing statistical significance at qRT-PCR level were taken forward to stain tissue microarray sections of SCLC and LCNEC to further delineate markers. This resulted in identification of BAI3, CDX2, VIL1 and CD99 as potential candidates. These markers were then taken forward to stain whole sections of tumour sample available in house (University Hospitals Coventry and Warwickshire) which resulted in elimination of CD99. Thus, BAI3, CDX2 and VIL1 were taken further forward to stain tumour samples acquired externally in UK. Four Small cell lung carcinoma, four large cell neuroendocrine carcinoma and seven background lungs were laser microdissected and profiled on Agilent SurePrint G3 human gene expression 8x60K single channel array to identify potential markers for their classification and validated using qRT-PCR and immunohistochemistry.

2013-11-01 | E-GEOD-44447 | biostudies-arrayexpress

BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas

2013-11-01 | GSE44447 | GEO